Table of Content

1. Introduction
1.1. Product Definition
1.2. Research Process
1.3. Assumptions
1.4. Market Definition

2. Executive Summary

3. Middle East & Africa Dermatology Drug Market Outlook 2016-2026F
3.1. Market Size & Analysis
3.1.1. By Revenues
3.2. Market Share & Analysis
3.2.1. By Drug Type
3.2.1.1. Branded
3.2.1.2. Generics
3.2.2. By Drug Class
3.2.2.1. Corticosteroids
3.2.2.2. Retinoid
3.2.2.3. Monoclonal Antibodies
3.2.2.4. Antibiotics Agents
3.2.2.5. Antiviral Agents
3.2.2.6. Antifungal Drugs
3.2.2.7. Antihistamines Agents
3.2.2.8. Immunosuppressive Drugs
3.2.3. By Application
3.2.3.1. Psoriasis
3.2.3.2. Atopic dermatitis
3.2.3.3. Acne
3.2.3.4. Rosacea
3.2.3.5. Skin cancer
3.2.3.6. Scar
3.2.3.7. Others
3.2.4. By End-User
3.2.4.1. Hospitals
3.2.4.2. Cosmetic Centers
3.2.4.3. Dermatology Clinics
3.2.4.4. Homecare
3.2.4.5. Others
3.2.5. By Prescription Mode
3.2.5.1. Prescription Based Drugs
3.2.5.2. Over The Counter (OTC) Drugs
3.2.6. By Route of Administration
3.2.6.1. Topical
3.2.6.2. Oral
3.2.6.3. Parenteral
3.2.7. By Distribution Channel
3.2.7.1. Direct
3.2.7.2. Retail/wholesale
3.2.7.3. Online
3.2.8. By Country
3.2.8.1. UAE
3.2.8.2. Saudi Arabia
3.2.8.3. Qatar
3.2.8.4. Turkey
3.2.8.5. South Africa
3.2.8.6. Others
3.2.9. By Company
3.2.9.1. Revenue Shares
3.2.9.2. Strategic Factorial Indexing
3.2.9.3. Competitor Placement in MarkNtel Quadrant

4. UAE Dermatology Drug Market Outlook 2016-2026F
4.1. Market Size & Analysis
4.1.1. By Revenues
4.2. Market Share & Analysis
4.2.1. By Drug Type
4.2.2. By Drug Class
4.2.3. By Application
4.2.4. By End-User
4.2.5. By Prescription Mode
4.2.6. By Distribution Channel
4.2.7. By Route of Administration

5. Saudi Arabia Dermatology Drug Market Outlook 2016-2026F
5.1. Market Size & Analysis
5.1.1. By Revenues
5.2. Market Share & Analysis
5.2.1. By Drug Type
5.2.2. By Drug Class
5.2.3. By Application
5.2.4. By End-User
5.2.5. By Prescription Mode
5.2.6. By Distribution Channel
5.2.7. By Route of Administration

6. Qatar Dermatology Drug Market Outlook 2016-2026F
6.1. Market Size & Analysis
6.1.1. By Revenues
6.2. Market Share & Analysis
6.2.1. By Drug Type
6.2.2. By Drug Class
6.2.3. By Application
6.2.4. By End-User
6.2.5. By Prescription Mode
6.2.6. By Distribution Channel
6.2.7. By Route of Administration

7. Turkey Dermatology Drug Market Outlook 2016-2026F
7.1. Market Size & Analysis
7.1.1. By Revenues
7.2. Market Share & Analysis
7.2.1. By Drug Type
7.2.2. By Drug Class
7.2.3. By Application
7.2.4. By End-User
7.2.5. By Prescription Mode
7.2.6. By Distribution Channel
7.2.7. By Route of Administration

8. South Africa Dermatology Drug Market Outlook 2016-2026F
8.1. Market Size & Analysis
8.1.1. By Revenues
8.2. Market Share & Analysis
8.2.1. By Drug Type
8.2.2. By Drug Class
8.2.3. By Application
8.2.4. By End-User
8.2.5. By Prescription Mode
8.2.6. By Distribution Channel
8.2.7. By Route of Administration

9. Middle East & Africa Dermatology Drug Market Regulations

10. Middle East & Africa Dermatology Drug Market Trends & Insights

11. Middle East & Africa Dermatology Drug Market Dynamics
11.1. Growth Drivers
11.2. Challenges
11.3. Impact Analysis

12. Middle East & Africa Dermatology Drug Market Hotspot and Opportunities

13. Middle East & Africa Dermatology Drug Market Key Strategic Imperatives for Success and Growth

14. Competition Outlook
14.1. Competition Matrix
14.1.1. Target Markets
14.1.2. Target End Users
14.1.3. Research & Development
14.1.4. Strategic Alliances
14.1.5. Strategic Initiatives
14.2. Company Profiles (Business Description, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
14.2.1. Bausch Health Companies Inc.
14.2.2. Novartis AG
14.2.3. Pfizer Inc.
14.2.4. Bristol-Myers Squibb Company
14.2.5. Johnson & Johnson
14.2.6. Merck & Co. Inc.
14.2.7. Amgen Inc.
14.2.8. AbbVie Inc.
14.2.9. Eli Lilly and Company
14.2.10. Galderma S.A.
14.2.11. GlaxoSmithKline plc
14.2.12. Mylan N.V.

15. Disclaimer